Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call
March 04 2021 - 11:15AM
Orgenesis Inc. (NASDAQ: ORGS)
(“Orgenesis” or the “Company”), a global biotech company working to
unlock the full potential of cell and gene therapies, today
announced that it plans to host a conference call at 8:30 AM
Eastern Time on Tuesday, March 9, 2021 to discuss the Company’s
financial results for the 2020 fiscal year ended December 31, 2020,
as well as the Company’s corporate progress and other developments.
The conference call will be available via telephone by dialing
toll free 877-545-0320 for U.S. callers or +1 973-528-0016 for
international callers and using entry code 796258. A webcast of the
call may be accessed at
https://www.webcaster4.com/Webcast/Page/2585/40294 or on the
Company’s Investor Events section of the website here.
A webcast replay will be available on the Company’s Investor
Events section of the website (https://ir.orgenesis.com/overview#/)
through Wednesday, March 9, 2022. A telephone replay of the call
will be available approximately one hour following the call,
through Tuesday, March 23, 2021 and can be accessed by dialing
877-481-4010 for U.S. callers or +1 919-882-2331 for international
callers and entering conference ID: 40294.
About OrgenesisOrgenesis is a
global biotech company working to unlock the full potential of
cell and gene therapies (CGTs) in an affordable and accessible
format at the point of care. The Orgenesis
POCare Platform is comprised of three
enabling components: a pipeline of licensed POCare
Therapeutics that are processed and produced in
closed, automated POCare
Technology systems across a
collaborative POCare Network.
Orgenesis identifies promising new therapies and leverages its
POCare Platform to provide a rapid, globally harmonized pathway for
these therapies to reach and treat large numbers of patients at
lowered costs through efficient, scalable, and decentralized
production. The POCare Network brings together patients, doctors,
industry partners, research institutes and hospitals worldwide to
achieve harmonized, regulated clinical development and production
of the therapies. Learn more about the work Orgenesis is doing
at www.orgenesis.com.
Contact for Orgenesis:David WaldmanCrescendo
Communications, LLCTel: 212-671-1021
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Apr 2023 to Apr 2024